

This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike License](https://creativecommons.org/licenses/by-nc-sa/4.0/). Your use of this material constitutes acceptance of that license and the conditions of use of materials on this site.




Copyright 2006, The Johns Hopkins University and Sean T. Prigge. All rights reserved. Use of these materials permitted only in accordance with license rights granted. Materials provided "AS IS"; no representations or warranties provided. User assumes all responsibility for use, and all liability related thereto, and must independently review all materials for accuracy and efficacy. May contain materials owned by others. User is responsible for obtaining permissions for use from third parties as needed.

New Drug Targets

Sean T. Prigge, PhD

MMV

MMV Portfolio 2nd Quarter 2006



Attrition

Projects	Objectives	Success Rates
Discovery		
<ul style="list-style-type: none">• Exploratory	Target identification Target biochemistry Develop screening assay Develop X-ray crystallography	30% of projects will move to the next stage
<ul style="list-style-type: none">• Lead Identification	High throughput screening for identification of Hits	65% of projects will move to the next stage
<ul style="list-style-type: none">• Lead Optimization	SAR and molecular modeling to increase activity against parasite Improve pharmacokinetics Decrease toxicity	55% of projects will move to the next stage
Development		
<ul style="list-style-type: none">• Preclinical Transition	Evaluation of toxicology Absorption, distribution, metabolism and excretion	55% of projects will move to the next stage
<ul style="list-style-type: none">• Phase 1	First time in humans Safety and tolerability Pharmacokinetics 20 to 80 subjects exposed	70% of projects will move to the next stage
<ul style="list-style-type: none">• Phase 2	Dose determining studies Early side-effect profile 200 to 300 subjects exposed	50% of projects will move to the next stage
<ul style="list-style-type: none">• Phase 3	Large safety and efficacy studies Risk benefit 1000 to 3000 subjects exposed	65% of projects will move to registration
<ul style="list-style-type: none">• Registration/Regulatory Approval	Drug available to patients	95% go on to drugs


Attrition

There are several reasons for the high dropout rate:

- ◆ a biologically poor target
- ◆ lack of activity against the target or parasite
- ◆ toxicity
- ◆ tolerability
- ◆ cost of goods


MMV

MMV Portfolio 2nd Quarter 2006




Malaria Parasite


Red Blood Cell Infection by *Plasmodium falciparum*



Mitochondrial Origin



Apicoplast Origin



Oranellar Genomes

Mitochondrion (6 Kbp)

cytochrome oxidase I
cytochrome oxidase I
cytochrome oxidase III

Apicoplast (35 Kbp)

Full set of tRNAs
Clp protease
Elongation Factor TU
ABC transport involved
in Fe-S assembly
6 ORFs of less than 100 AA

Nuclear Genome

5300 genes

Mitochondrial Import

246 possible

148 likely

Apicoplast Import

551 possible

126 likely


(*<1000 plastid proteins in A. thal*)

Metabolic Pathways


	Human	Plant	Malaria
Tricarboxylic Acid Cycle	Mito	Mito	?
Porphyrin Biosynthesis	Mito	Mito + Chlor	?
Shikimate Pathway	No	Chlor	?
Isoprenoid Biosynthesis Mevalonate	Cytosol	Cytosol	?
DOXP	No	Chlor	?
Fatty Acid Biosynthesis Type I	Cytosol	Cytosol	?
Type II	No	Chlor	?

<http://www.genome.jp/kegg/pathway.html>


TCA Cycle




No Pyruvate Dehydrogenase Complex




No Pyruvate Dehydrogenase Complex



TCA Cycle





No Pyruvate Dehydrogenase Complex



Metabolic Pathways



	Human	Plant	Malaria
Tricarboxylic Acid Cycle	Mito	Mito	Mito
Porphyrin Biosynthesis	Mito	Mito + Chlor	?
Shikimate Pathway	No	Chlor	?
Isoprenoid Biosynthesis Mevalonate	Cytosol	Cytosol	?
DOXP	No	Chlor	?
Fatty Acid Biosynthesis Type I	Cytosol	Cytosol	?
Type II	No	Chlor	?

Porphyrin Biosynthesis







Porphyrin Biosynthesis

Apicoplast



Mitochondrion

Apicoplast



Metabolic Pathways

Human

Plant

Malaria

Tricarboxylic Acid Cycle

Mito

Mito

Mito

Porphyrin Biosynthesis

Mito

Mito + Chlor

$\frac{1}{2}$ Mito
 $\frac{1}{2}$ Apico

Shikimate Pathway

No

Chlor

?

Isoprenoid Biosynthesis Mevalonate

Cytosol

Cytosol

?

DOXP

No

Chlor

?

Fatty Acid Biosynthesis Type I

Cytosol

Cytosol

?


Type II

No


Chlor

?

Shikimate Pathway




Chorismate



Shikimate Pathway

- No predicted oranelar targeting.
- CS localized to cytosol by immunomicroscopy



Metabolic Pathways

	Human	Plant	Malaria
Tricarboxylic Acid Cycle	Mito	Mito	Mito
Porphyrin Biosynthesis	Mito	Mito + Chlor	1/2 Mito 1/2 Apico
Shikimate Pathway	No	Chlor	Cytosol
Isoprenoid Biosynthesis Mevalonate	Cytosol	Cytosol	?
DOXP	No	Chlor	?
Fatty Acid Biosynthesis Type I	Cytosol	Cytosol	?
Type II	No	Chlor	?

Isoprenoid Biosynthesis


Mevalonate-dependent

4 steps from 3-hydroxy methylglutaryl-Coa to
Isopentenyl-PP (V,L,I degradation)
Typically supports terpenoid and sterol biosynthesis

Mevalonate-independent

DOXP (1-deoxy D-xylulose 5-phosphate)

Isoprenoid Biosynthesis



Metabolic Pathways

	Human	Plant	Malaria
Tricarboxylic Acid Cycle	Mito	Mito	Mito
Porphyrin Biosynthesis	Mito	Mito + Chlor	$\frac{1}{2}$ Mito $\frac{1}{2}$ Apico
Shikimate Pathway	No	Chlor	Cytosol
Isoprenoid Biosynthesis Mevalonate	Cytosol	Cytosol	No
DOXP	No	Chlor	Apico
Fatty Acid Biosynthesis Type I	Cytosol	Cytosol	?
Type II	No	Chlor	?

Fatty Acid Biosynthesis

Type I Fatty Acid Synthase

Multifunctional enzyme (one or two polypeptides)
Found in most eukaryotic cells

Type II Fatty Acid Synthase

Enzymes expressed as separate proteins
Found in plants and microorganisms

Fatty Acid Biosynthesis



Type I Fatty Acid Synthase

Multifunctional enzyme (one or two polypeptides)
Found in most eukaryotic cells


**7 genes
found**

Type II Fatty Acid Synthase


Enzymes expressed as separate proteins
Found in plants and microorganisms

Type II FAS


Kyoto Encyclopedia of Genes and Genomes




Type II FAS




Type II FAS





Type II FAS



Type II FAS




Acetyl-CoA




Malonyl-CoA

Dims, Fops

Type II FAS



Type II FAS



Metabolic Pathways

	Human	Plant	Malaria
Tricarboxylic Acid Cycle	Mito	Mito	Mito
Porphyrin Biosynthesis	Mito	Mito + Chlor	1/2 Mito 1/2 Apico
Shikimate Pathway	No	Chlor	Cytosol
Isoprenoid Biosynthesis Mevalonate	Cytosol	Cytosol	No
DOXP	No	Chlor	Apico
Fatty Acid Biosynthesis Type I	Cytosol	Cytosol	No
Type II	No	Chlor	Apico

Two Conclusions

1. Apicoplast = reducing environment
Reactions sensitive to oxidizing environment
2. Close association between mitochondrion and apicoplast
Heme biosynthesis

Sharing of:

Acetyl-CoA

tRNA-Ligases

Fe-S

Lipoate

